Russian tennis ace Maria Sharapova on Monday admitted to failing a drug test at the Australian Open in January, an act that will get her suspended from tennis, BBC reported .
Sharapova, in a press conference in Los Angeles on Monday, said she had been taking the drug, meldonium, ever since 2006 and didn't realise that it became a banned substance by the World Anti-Doping Agency (WADA) at the start of 2016.
The International Tennis Federation, about an hour after her admission, said on its website that the 28-year-old would be provisionally banned from March 12. The usual ban for first-time offenders is two years.
The failed drug test came on January 26 -- after Sharapova lost to Serena Williams in the quarterfinals -- and she was charged with an anti-doping violation on March 2, the governing body additionally said.
"A few days ago I received a letter from the (International Tennis Federation) that I failed a drug test at the Australian Open," Sharapova, who has long been the world's richest female athlete, said in the press conference.
"I did fail the test and take full responsibility for it. For the past 10 years I have been given a medicine called mildronate by my doctor, my family doctor, and a few days ago after I received the ITF letter I found out that it also has another name, meldonium, which I did not know.
"It's very important for you to understand for 10 years this medicine was not on WADA's banned list and I had been legally taking the medicine for the past 10 years. But on January 1 the rules had changed and meldonium became a prohibited substance, which I had not known," the five-time grand slam winner said.
Sharapova said she began taking the medication, which can be used to treat heart issues, after irregular EKGs and being deficient in magnesium. Her family also has a history of diabetes, she added.
WADA stated in September that the anti-ischemic drug would be added to the prohibited list and Sharapova blamed herself for not taking note of the new list.
Steve Simon, CEO of the WTA women's tour, was "saddened" by the development but said it was down to Sharapova to make sure she knew the rules, the BBC report said.
"I am very saddened to hear this news about Maria," he said in a statement. "Maria is a leader and I have always known her to be a woman of great integrity. Nevertheless, as Maria acknowledged, it is every player's responsibility to know what they put in their body and to know if it is permissible.
"This matter is now in the hands of the Tennis Anti-Doping Program and its standard procedures. The WTA will support the decisions reached through this process."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
